The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...
On March 18th, the FDA published draft guidance on validating new approach methodologies (NAMs), including complex in vitro ...
The top drug regulator at the US Food and Drug Administration (FDA) said the agency is working to develop new pathways for ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The corporate logo of the U.S. Food and Drug Administration (FDA) is shown in Silver Spring, Maryland, November 4, ...
Please provide your email address to receive an email when new articles are posted on . The FDA announced plans in 2025 to reduce animal testing requirements in biomedical research. New approach ...
The U.S. Food and Drug Administration issued a draft guidance on Wednesday to help drug developers validate alternative methods that can be used in place of animal studies during early stages of drug ...
Add Yahoo as a preferred source to see more of our stories on Google. FDA headquarters in White Oak, Maryland (Sarah Silbiger via Getty Images) This story was originally published on PharmaVoice. To ...
As regulatory authorities accelerate the use of New Approach Methodologies (NAMs), the drug discovery landscape is changing dramatically. This webinar explores how NAMs, immunology-driven platforms, ...
WEST LAFAYETTE, Ind., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug ...
DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0, Advancing Human‑Relevant New Approach Methodologies (NAMs) ZURICH/SCHLIEREN, Switzerland, December 24, 2025 – DiNABIOS AG, ...
Under the new draft guidance, the FDA has recommended using newer non‑animal testing tools - known as new approach methodologies, or NAMs - when companies submit nonclinical safety data to support a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results